New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
09:01 EDTINOFollow-up: Inovio 18.9M share Spot Secondary priced at $2.90
The deal range was raised to 18.9M shares from 13.4M shares. Piper Jaffray and Stifel acted as joint book running managers for the offering.
News For INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2016
07:25 EDTINOBiotech Industry Organization to hold a conference
Subscribe for More Information
February 2, 2016
14:52 EDTINOZika virus acquired through sexual transmission reported in Dallas
Dallas County Health and Human Services announced it has received confirmation from the Centers for Disease Control and Prevention of the first Zika virus case acquired through sexual transmission in Dallas County in 2016. The patient was infected with the virus after having sexual contact with an ill individual who returned from a country where Zika virus is present, DCHHS reported. Publicly traded companies working on combating Zika include Inovio (INO), Cerus (CERS), NewLink (NLNK) and Intrexon (XON).
12:56 EDTINOMizuho downplays near-term Zika revenue potential for NewLink, Intrexon
The Zika virus and its link to microcephaly and fetal brain damage have exploded into public view and lead to several drugmakers announcing plans to fight the disease, but Mizuho analyst Eric Criscuolo downplayed the potential for Zika to truly move the needle for companies in the space in the near-term. PERIPHERAL OPPORTUNITIES: NewLink (NLNK) announced plans to develop treatment options for the Zika virus as the disease was declared a global health emergency by the World Health Organization this week. While the company "could" secure funding and partnerships for the project, Criscuolo does not view NewLink's Zika plans as core to its investment story, encouraging investors to instead evaluate the company on the basis of its HyperAcute and IDO programs. Meanwhile, Intrexon's (XON) efforts in mosquito population control have also gained attention amid the rise of Zika, whose primary transmission vector is the mosquito. Though even a small slice of global mosquito spending would represent "significant" revenue for Intrexon, Criscuolo cautions that the company's program is still in early stages, with attempts at a wider rollout likely encountering political, biological, financial and public opinion hurdles. Separately, the analyst said he wouldn't be surprised to see OraSure (OSUR) also attempt to develop a Zika test given the company's response to Ebola last year, though as with NewLink, Criscuolo believes any such effort would be peripheral to OraSure's primary businesses. OTHERS TO WATCH: Other publicly traded companies involved in combating Zika include Inovio (INO) and Cerus (CERS). PRICE ACTION: Shares of NewLink are up roughly 5% to $25.63. Meanwhile, Intrexon has slipped 5.5% on Tuesday afternoon but is still up 15% over the last five trading days. Among others with links to Zika, OraSure is up fractionally, Inovio has fallen 7% and Cerus has dipped 1.4% this afternoon.
February 1, 2016
13:42 EDTINOWHO declares Zika virus to be global emergency, Reuters reports
Subscribe for More Information
05:57 EDTINOInovio volatility elevated, developing vaccine for Zika virus infection
Inovio February call option implied volatility is at 108, March is at 100; compared to its 52-week range of 49 to 115, suggesting large price movement as the company develops a DNA-based vaccine for preventing and treating the Zika virus infection.
January 29, 2016
13:19 EDTINOOptions with increasing call volume: EXP FLIR SYN INO PBR VMEM EPI GILD EA
Subscribe for More Information
10:03 EDTINOHigh option volume stocks: GIMO CSOD NAVI ALGN IMPV LC INO FMC VMW RCII
Subscribe for More Information
09:21 EDTINOOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Gigamon (GIMO), up 17.7%... Fortinet (FTNT), up 10%... Flextronics (FLEX), up 10%... Skyworks (SWKS), up 5.7%... Seagate Technology (STX), up 4.9%.. Microsoft (MSFT), up 4.6%. ALSO HIGHER: Inovio Pharmaceuticals (INO), up 8.1% after CEO says Zika vaccine could enter human testing this year... J.C. Penney (JCP), up 2.1% after being upgraded to Neutral from Underperform at Credit Suisse... BRF S.A. (BRFS), up 3.1% after being upgraded to Buy from Hold at Deutsche Bank... Axiall (AXLL), up 83.4% after rejecting $20 per share acquisition proposal from Westlake Chemical (WLK)... Energous (WATT), up 12% after Bloomberg reported that Apple (AAPL) is working with partners in the U.S. and Asia to develop new wireless charging technology. DOWN AFTER EARNINGS: Amazon.com (AMZN), down 10.1%... Electronic Arts (EA), down 6.2%... AbbVie (ABBV), down 4%... American Airlines (AAL), down 1.3%. ALSO LOWER: Gilead Sciences (GILD), down 5.5% after CEO John Martin to assume role of executive chairman and COO John Milligan will be promoted to CEO.
08:52 EDTINOInovio rises as CEO says Zika vaccine could enter human testing this year
Inovio Pharmaceuticals (INO) shares are rising again this morning as the Zika virus continues to gain attention and its CEO says the company is "ahead of the pack" in developing a vaccine to combat the disease. YEAR END TESTING POSSIBLE: Joseph Kim, CEO of Inovio, said making a vaccine available by the end of this year is aggressive, but possible, according to Reuters, which quoted Kim as saying, "I believe this will be the first to go into human testing. We believe we're ahead of the pack in the race for a Zika vaccine." WHAT'S NOTABLE: The head of the World Health Organization, Dr. Margaret Chan, said the Zika virus, which has been linked to neurological ailments, especially in fetuses and newborns, is "now spreading explosively" in the Americas. WHO now predicts that Zika could infect as many as 4M people in the Americas. ANOTHER TO WATCH: Cerus (CERS) is also at work on combating Zika. A study, partially funded by Cerus, showed that amotosalen combined with UVA light inactivates Zika virus in fresh-frozen plasma, according to an earlier report. PRICE ACTION: Inovio shares, which gained over 7.5% yesterday, are up another 9% to $6.30 in pre-market trading.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use